MARKET

KALA

KALA

Kala Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.94
-0.89
-9.05%
After Hours: 8.95 +0.01 +0.11% 18:36 09/21 EDT
OPEN
9.70
PREV CLOSE
9.83
HIGH
9.70
LOW
8.84
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
14.68
52 WEEK LOW
3.240
MARKET CAP
501.18M
P/E (TTM)
-3.9479
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Dow Rises 350 Points; Cassava Sciences Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.27% to 28,016 while the NASDAQ rose 1.74% to 11042.51. The S&P also rose, gaining 1.41% to 3,387.94.
Benzinga · 09/14 18:32
Mid-Day Market Update: Immunomedics Jumps Following Acquisition News; Mallinckrodt Shares Slide
Midway through trading Monday, the Dow traded up 1.38% to 28046.83 while the NASDAQ rose 2.41% to 11,114.71. The S&P also rose, gaining 1.73% to 3,398.74.
Benzinga · 09/14 16:07
Immunomedics, Cassava Sciences leads gainers pack, Nano-X Imaging, Teligent among major losers
Gainers: Immunomedics (IMMU) +101%, Cassava Sciences, (SAVA) +78%, Vaxart (VXRT) +28%, Mersana Therapeutics (MRSN) +17%, Venus Concept (VERO) +15%.Losers: Nano-X Imaging (NNOX) -14%, Teligent (TLGT) -12%, Mallinckrodt (MNK) -12%, Kala Pharmaceuticals (KALA) -12%, Co-Diagnostics (CODX) -11%.
Seekingalpha · 09/14 15:06
Mid-Morning Market Update: Markets Open Higher; Nvidia Reports $40B Deal To Buy SoftBank's Arm Holdings
Following the market opening Monday, the Dow traded up 1.40% to 28052.12 while the NASDAQ rose 2.31% to 11104.34. The S&P also rose, gaining 1.77% to 3,400.27.
Benzinga · 09/14 14:27
Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for
Business Wire · 09/10 13:00
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of its management team will participate virtually in the following upcoming conferences:
Business Wire · 09/08 13:00
Have Insiders Been Buying Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Simply Wall St. · 08/27 16:00
Kala Pharmaceuticals (KALA) Corporate Presentation - Slideshow
The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 08/07 19:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KALA stock price target is 19.83 with a high estimate of 39.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 168
Institutional Holdings: 51.70M
% Owned: 92.22%
Shares Outstanding: 56.06M
TypeInstitutionsShares
Increased
46
6.81M
New
62
-257.87K
Decreased
22
3.86M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.98%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mark Iwicki
Chief Financial Officer/Treasurer
Mary Reumuth
Chief Operating Officer
Todd Bazemore
Senior Vice President
Vincent Kosewski
Chief Scientific Officer
Hongming Chen
Senior Vice President
Michele LaRussa
Chief Compliance Officer/General Counsel/Secretary
Eric Trachtenberg
Other
Kim Brazzell
Lead Director/Independent Director
Andrew Koven
Independent Director
Gregory Grunberg
Independent Director
Robert Paull
Independent Director
Gregory Perry
Independent Director
Howard Rosen
Independent Director
Rajeev Shah
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average KALA stock price target is 19.83 with a high estimate of 39.00 and a low estimate of 10.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KALA
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kala Pharmaceuticals Inc stock information, including NASDAQ:KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.